Prevalence and Associated Factors of Polypharmacy in Nursing Home Residents: A Cross-Sectional Study

Raquel Cadenas 1, María José Diez 1, Nélida Fernández 1, Juan José García 1, Ana M. Sahagún 1,*, Matilde Sierra 1, Cristina López 1, Julen Susperregui 2 and Raquel Diez 1

Abstract: In Spain, there has been a progressive increase in aging. Specifically, Leon has been one of the Spanish provinces with the highest aging index. Polypharmacy is highly prevalent among the elderly, with significant consequences for safety. The aim of this study was to assess the consumption of drugs in a nursing home in the province of Leon and establish the relationship between polypharmacy and the most common comorbid diseases. A descriptive, observational, and cross-sectional study design was used. Residents’ information and treatments were collected by reviewing on medical charts, completed with clinical information obtained from the physician of the nursing home. The mean age of residents was 86.8 years, and 63.8% were female. Mean medical consumption amounted to 7.02 prescriptions. Polypharmacy was observed in 54.9% of residents, and excessive polypharmacy in 22.1%. The most commonly used medications (ATC classification) were those acting on the cardiovascular system (84.4%) and the nervous system (82.8%). A high-level of drug consumption was observed in the nursing home. Interventions should focus on those residents hospitalized the last year and with recent contact with a general practitioner. There is a need to develop a comprehensive monitoring system to assess the quality of prescriptions for nursing home residents.

Keywords: aging; elderly; medication; nursing home; polypharmacy; public health

1. Introduction

Aging is a global phenomenon that affects especially the most developed countries. In Spain, it is increasing dramatically: people aged 65 and over represented 19.1% of the Spanish population in 2017, with approximately one-third over 80 years (6.2% of the Spanish population). Moreover, it is estimated that in 2050 Spanish population aged 65 and over will exceed 30%, and if only people aged 80 and over are considered, they will account for 12% of the Spanish population [1]. Castile-Leon is the region with the highest proportion of people over 64 years (24.4%) [2]. In this region, Leon is the second province with the highest aging index (2.41) in 2020 (calculated as the proportion between the Spanish population in 2017, with approximately one-third over 80 years (6.2% of the Spanish population)). Moreover, it is estimated that in 2050 Spanish population aged 65 and over will exceed 30%, and if only people aged 80 and over are considered, they will account for 12% of the Spanish population [1]. Castile-Leon is the region with the highest proportion of people over 64 years (24.4%) [2]. In this region, Leon is the second province with the highest aging index (2.41) in 2020 (calculated as the proportion between people over the age of 64 and under age 16) [3]. Aging is a dynamic, complex and continuous process characterized by a rising susceptibility to the occurrence of multiple chronic diseases (comorbidity) that often results in the concomitant use of multiple drug therapies (polypharmacy) for treatment and prophylaxis.

The World Health Organization (WHO) defines polypharmacy as “the administration of many drugs at the same time or the administration of an excessive number of drugs” [4]. Although this term is not uniformly defined in the literature, the most commonly used definition considers that five or more drugs are taken daily [5–10]. Polypharmacy in the elderly is increasing and has been identified as a medication safety issue. The risk of an
adverse event raises exponentially for five medications [11,12]. Surveys estimate that more than 60% of people over 65 are being prescribed three or more medications on a daily basis, and about 39% have more than five prescriptions [13,14]. Polypharmacy increases the risk of adverse drug-related events in older adults as a higher number of drugs comes with a higher risk of drug–drug interactions. Moreover, the aging process is associated with physiological changes that make the elderly more prone to adverse drug reactions [15].

Nursing home (NH) residents are no exception in polypharmacy. Moreover, they are usually frail and present multiple chronic diseases and a high rate of functional and cognitive impairment. Spain had more than 372,000 beds for nursing and residential care facilities in 2016 [2], and about 4.3% of the elderly were NH residents. They were an average age of 83 years old and 65% dependent on others for daily care needs. Castile-Leon had 45,783 places in residential centers, with an occupancy rate of 100% [2].

Several international experts have recognized the need to perform epidemiological and clinical research in NH [16,17]. It is consequently important to monitor polypharmacy in this group of the elderly population and explore those factors that contribute to it. Given the high percentage of the institutionalized elderly population in Leon, they would become a representative sample to evaluate drug consumption and the prevalence of chronic diseases in order to plan health resources and effective interventions. Hence, the aim of this study was to assess the consumption of drugs in a Spanish nursing home of the province of Leon and to establish if polypharmacy is related to the most common comorbid diseases.

2. Materials and Methods

A descriptive, observational, and cross-sectional study was carried out in a Spanish NH located in the province of Leon. Information on institutionalized elderly and their treatments were collected from January to June 2019 by one of the nurses of the NH (first author of the paper), who reviewed on medical charts, completing it with clinical information obtained from the physician of the NH. Retrieved data included demographic characteristics of the residents (age, gender, and origin), length of stay, contacts in the past 2 months with a general practitioner (GP), hospitalization in the past 12 months, pathologies, and medications. Only residents aged ≥65 and institutionalized for at least 1 month were considered. Inclusion criteria for recorded medication were as follows: chronic treatments given orally, by inhalation, or eye drops, administrated for at least 1 month prior to data collection. Treatments initiated less than one month before data collection, complementary, over-the-counter (OTC) medications and nutritional supplements were excluded. Data collection was authorized by the NH directorship. Data were recorded from the NH management software on an Excel sheet. To guarantee the confidentiality of data and the identity of residents, no individual identifiers were used. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement was used to report data [18].

The Anatomical Therapeutic and Chemical Classification (ATC) [19] until the 5th level was employed to code medicines. Any combination medicine (multiple component products) was considered as a single medicine. Medicines with different brand names and generics having the same ATC code were considered as one medicine. All medications included in this study needed prescription.

The necessary minimum sample size was estimated in 267 residents, assuming a precision of 0.06, an estimated probability of 0.5 and a significance level of 0.5. The NH was chosen as it exceeds the minimum sample size, obtaining better precision.

2.1. Statistical Analysis

Descriptive statistics (frequencies, means, standard deviations, and ranges) were used to characterize the study population. According to previous publications, polypharmacy status was categorized into 3 groups: non-polypharmacy (0–4 medicines), polypharmacy (5–9 medicines) and excessive polypharmacy (at least 10 medicines) [20–26].
The chi-squared test was employed for the comparison of categorical variables. In addition, logistic regression was performed to identify those variables associated with polypharmacy. The odds ratio (OR) was calculated with their respective 95% confidence intervals (95% CI). A $p$-value of <0.05 was used as the significance level. Data analysis was performed with the statistical package SPSS Statistics version 26 (IBM Corporation, Armonk, NY, USA).

2.2. Ethical Considerations

The study was approved by the Institutional Review Board of the Nursing Home and the Ethics Committee of the University of Leon (ULE-0382018) and carried out in accordance with the Declaration of Helsinki.

3. Results

Three hundred twenty-six residents were included in this study. Their mean age was 86.8 ± 7.5 years (range 67–107 years), being 63.8% women (Table 1). Residents had mostly lived in the NH less than 5 years (52.2%), they had previously lived in their homes (65.9%), had contact in the past 2 months with a GP (65.0%), and did not require hospitalization in the past 12 months (69.9%). The mean number of medicines used per person was 7.02 ± 3.31 (range: 0–17).

Table 1. Characteristics of the residents in the nursing home (NH) studied, stratified by the level of polypharmacy.

| Characteristic                        | All ($n = 326$) | Non-Polypharmacy (0–4 Drugs) ($n = 75$) | Polypharmacy (5–9 Drugs) ($n = 179$) | Excessive Polypharmacy (≥10 Drugs) ($n = 72$) |
|---------------------------------------|----------------|----------------------------------------|--------------------------------------|---------------------------------------------|
|                                       | %              | 95% CI                                 | %                                    | 95% CI                                      | %              | 95% CI                                      |
| Sex                                   |                |                                        |                                      |                                             |                |                                             |
| Males                                 | 36.2           | 30.9–41.4                              | 38.7                                 | 27.7–49.7                                   | 31.8           | 25.0–38.7                                   | 44.4           | 32.9–55.9                                   |
| Females                               | 63.8           | 58.9–69.0                              | 61.3                                 | 50.3–72.4                                   | 68.2           | 61.3–74.9                                   | 55.6           | 44.1–67.0                                   |
| Age (years) ($n = 319$)               |                |                                        |                                      |                                             |                |                                             |
| 65–74                                 | 6.3            | 3.6–8.9                                | 7.0                                  | 1.1–13.0                                    | 6.2            | 2.7–9.8                                     | 5.6            | 0.3–11.0                                    |
| 75–84                                 | 27.9           | 23.0–32.8                              | 29.6                                 | 18.9–40.2                                   | 26.6           | 20.0–33.1                                   | 29.6           | 19.0–40.2                                   |
| 85–94                                 | 52.0           | 46.6–57.5                              | 47.9                                 | 36.3–59.5                                   | 52.0           | 44.6–59.3                                   | 56.3           | 44.9–67.9                                   |
| ≥95                                   | 13.8           | 10.0–17.6                              | 15.5                                 | 7.1–23.9                                    | 15.2           | 10.0–20.5                                   | 8.5            | 2.0–14.9                                    |
| Length of stay (years) ($n = 249$)   |                |                                        |                                      |                                             |                |                                             |
| <5                                    | 52.2           | 46.7–57.6                              | 49.3                                 | 38.0–60.7                                   | 52.0           | 44.6–59.3                                   | 55.6           | 44.1–67.0                                   |
| 5–10                                  | 29.1           | 24.2–34.1                              | 34.7                                 | 23.9–45.4                                   | 26.8           | 20.3–33.3                                   | 29.2           | 18.7–39.7                                   |
| 10–15                                 | 12.3           | 8.7–15.8                               | 13.3                                 | 5.6–21.0                                    | 13.4           | 8.4–18.4                                    | 8.3            | 2.6–14.7                                    |
| >15                                   | 6.4            | 3.8–9.1                                | 2.7                                  | 0–6.3                                       | 7.8            | 3.9–11.8                                    | 6.9            | 1.1–12.8                                    |
| Origin                                |                |                                        |                                      |                                             |                |                                             |
| Other NH                              | 17.5           | 13.3–21.6                              | 13.3                                 | 5.6–21.0                                    | 16.8           | 11.3–22.2                                   | 23.6           | 13.8–33.4                                   |
| Home                                  | 65.9           | 60.8–71.1                              | 66.7                                 | 56.0–77.3                                   | 68.7           | 61.9–75.5                                   | 58.3           | 46.9–69.7                                   |
| Prison                                | 0.6            | 0–1.46                                 | 0                                    | 0                                            | 0.6            | 0–1.7                                      | 1.4            | 0–4.1                                       |
| Unknown                               | 15.9           | 11.9–19.9                              | 20.0                                 | 10.9–29.1                                   | 13.9           | 8.9–19.0                                   | 16.7           | 8.1–22.3                                    |
| Contact with GP in past 2 months      |                |                                        |                                      |                                             |                |                                             |
| No                                    | 35.0           | 29.8–40.2                              | 42.7                                 | 31.5–53.9                                   | 35.8           | 28.7–42.8                                   | 25.0           | 15.0–35.0                                   |
| Yes                                   | 65.0           | 59.9–70.2                              | 57.3                                 | 46.1–68.5                                   | 64.2           | 57.2–71.3                                   | 75.0           | 65.0–85.0                                   |
| Hospitalization in past 12 months ($n = 249$) |            |                                        |                                      |                                             |                |                                             |
| No                                    | 61.9           | 56.6–67.1                              | 73.7                                 | 63.7–83.7                                   | 62.6           | 55.5–69.7                                   | 47.2           | 33.7–60.6                                   |
| Yes                                   | 38.1           | 32.9–43.4                              | 26.3                                 | 16.4–36.3                                   | 37.4           | 30.3–44.5                                   | 52.8           | 39.4–66.3                                   |

CI: confidence interval; GP: general practitioner.

Table 1 also summarizes the characteristics of the sample according to the polypharmacy status. Polypharmacy was observed in 54.9% of residents, and excessive polypharmacy in 22.1%. In these groups, resident profile followed a similar pattern to that of the total study population, though in the excessive polypharmacy group, males rose to 44.4%.
three-quarters had contact with a GP in the last two months, and more than half had been hospitalized in the last 12 months.

Multiple comorbidities were observed in most residents, with a median of 7.8 clinical problems per resident (range 0–21). 98.8% had two or more diseases diagnosed by the GP. The pathologies diagnosed for the study population and for each group of polypharmacy are summarized in the supplementary file (Supplementary Materials Table S1). High blood pressure (55.5%), cognitive impairment (34.1%) and bone fractures (34.0%) were the most frequent pathologies diagnosed. When both polypharmacy groups were compared, the prevalence of pathologies clearly increased in the excessive polypharmacy group, especially in the case of constipation (18.4% vs. 34.7%), diabetes (29.1% vs. 44.4%), dyslipidemia (27.4% vs. 42.2%), and bone fractures (31.8% vs. 40.3%). The opposite happened in the case of cognitive impairment (38.5% vs. 30.6%).

Moreover, the number of chronic medications was clearly related to the number of pathologies listed for each resident (Figure 1). Only in the group with the highest number of comorbidities the polypharmacy dropped.

![Relationship between polypharmacy and number of pathologies](image)

**Figure 1.** Relationship between polypharmacy and number of pathologies (0: no pathology; 1: 1–3 pathologies; 2: 4–6 pathologies; 3: 7–9 pathologies; 4: 10–12 pathologies; 5: 13–15 pathologies; 6: 16 or more pathologies).

Regarding the pattern of drug consumption by the NH residents with respect to the anatomical group of the ATC classification (first level) (Supplementary Materials Table S2), medicines active on the alimentary tract and metabolism were the most frequently used drugs (85.3%), followed by those acting on the cardiovascular (84.4%) and the nervous (82.8%) systems. A similar profile of consumption was observed when the population was grouped by their level of polypharmacy. Only in the case of group A (alimentary tract and metabolism), its consumption rose to 98.6% in the excessive polypharmacy group.

The ten most commonly used pharmacological subgroups (third level of ATC classification) are shown in Supplementary Materials Table S3. Drugs for peptic ulcer and gastro-esophageal reflux disease were the most commonly used in polypharmacy residents (86.1%) and the second one in the non-polymedicated group (36.0%).

The use of diuretics and antithrombotic agents was also common in the polypharmacy group (57.4% and 56.2%, respectively), with values clearly lower in non-polymedicated residents (18.7% and 16.0%, respectively). Consumption percentages of antidepressants were, however, similar in both groups.
When the 5th level of ATC classification is considered, the most commonly used active ingredients among the elderly in our study included omeprazole (45.7%), furosemide (44.2%), and acetylsalicylic acid (30.4%).

**Multivariate Analysis**

Table 2 summarizes the results of the multivariate analysis, identifying those variables associated with polypharmacy. Total polypharmacy (consumption of 5 or more drugs) was directly associated with a higher hospitalization in the last 12 months (OR = 2.0; 95% CI 1.04–3.85). A direct association between excessive polypharmacy and contact with a GP in the last 2 months (OR = 2.23; 95% CI 1.11–4.51) and with hospitalization in the last year (OR = 3.14; 95% CI 1.41–6.97) was also observed. When the three most consumed anatomical groups (ATC first level) were considered (Supplementary Materials Table S4), no significant association was obtained between these groups and the factors assessed, except when the origin of the residents was not known. These residents showed higher consumption of cardiovascular drugs (OR = 3.91; 95% CI 1.02–14.89).

**Table 2.** Factors associated with polypharmacy among residents in the NH studied (reference category: non-polypharmacy).

| Factor                  | Polypharmacy (5–9 Drugs) | Excessive Polypharmacy (≥10 Drugs) | Total Polypharmacy (≥5 Drugs) |
|-------------------------|--------------------------|-----------------------------------|-------------------------------|
|                         | Odds Ratio (95% CI)       | Odds Ratio (95% CI)               | Odds Ratio (95% CI)           |
| Gender Male             | 1.35 (0.77–2.37)          | 0.79 (0.41–1.52)                  | 1.15 (0.67–1.95)              |
| Age (years) (n = 319)   |                          |                                   |                               |
| 75–84                   | 1.19 (0.67–2.11)          | 1.06 (0.54–2.11)                  | 1.15 (0.66–1.99)              |
| 85–94                   | 0.88 (0.50–1.53)          | 0.75 (0.38–1.46)                  | 0.84 (0.49–1.43)              |
| ≥95                     | 1.06 (0.55–2.06)          | 1.78 (0.74–4.24)                  | 1.21 (0.64–2.30)              |
| Length of stay (years)  |                          |                                   |                               |
| <5                      | 0.73 (0.42–1.25)          | 0.65 (0.34–1.26)                  | 0.71 (0.42–1.19)              |
| 5–10                    | 1.12 (0.64–1.97)          | 1.05 (0.54–2.06)                  | 1.10 (0.65–1.88)              |
| 10–15                   | 0.71 (0.35–1.44)          | 1.06 (0.43–2.57)                  | 0.79 (0.39–1.57)              |
| Origin                  |                          |                                   |                               |
| Home                    | 0.65 (0.32–1.33)          | 0.81 (0.35–1.88)                  | 0.70 (0.36–1.36)              |
| Unknown                 | 1.12 (0.63–1.99)          | 0.72 (0.37–1.42)                  | 0.98 (0.57–1.70)              |
| Contact with GP in past 2 months (n = 249) | 1.34 (0.77–2.32) | 2.23 (1.11–4.51) | 1.53 (0.90–2.60) |
| Hospitalization in past 12 months | 1.67 (0.85–3.31) | 3.14 (1.41–6.97) | 2.0 (1.04–3.85) |

1 significant difference. CI: confidence interval; GP: general practitioner.

**4. Discussion**

Polypharmacy is a public health problem that is rising in parallel with a longer life expectancy of the population and a higher prevalence of chronic pathologies in older people. The present study examines the prevalence and factors associated with polypharmacy and excessive polypharmacy in a sample of NH residents in the province of Leon (Spain), with one of the most aged populations in this country. Thus, it would reflect a good approach to prescription trends in Spanish NH. Although it has not been possible to associate most of the factors assessed to polypharmacy, the study confirms the high consumption of medications in NH residents, as reported in other studies [24,25,27–30]. There has been a progressive increase in the number of medications consumed by the older population in recent years, possibly as the result of a combination of several factors, such as increased chronicity and morbidity in this group of the population, but also irrational drug use and increased availability of drugs [31–34]. On the other hand, NH residents usually have multiple clinical problems and, consequently, the number of medical treatments will be high.

Although the increase in the use of medications may mean greater access to treatments, better approaches to disease and improved quality of life, polypharmacy are becoming a
critical problem for national health systems, as it causes a multitude of problems in older people, such as a higher risk of drug–drug interactions and adverse drug reactions, hospitalizations, and mortality if potentially inappropriate medicines are administered [35–38]. Polypharmacy also increases the risk of vulnerability among the elderly, as does the probability of falls, fractures, cognitive impairment, urinary incontinence and delirium [35].

Increasing age is, however, associated with a lower prevalence of excessive polypharmacy, as in other studies [24,30]. This fact probably reflects the lack of data on the benefits of chronic therapies in very old people [24,27,39] and the reduced use of medications in those persons with a limited life expectancy [40].

Cognitive impairment is also associated with a reduced rate of excessive polypharmacy. As reflected the Beers criteria of the American Geriatrics Society [41] and the STOPP/START criteria [42], there is a need to avoid drugs that may affect cognition or induce delirium and behavioral symptoms when treating older adults with coexisting cognitive impairment, which could explain the lower use of drugs in older people.

As explained previously, the most frequently used active ingredients (5th level) were omeprazole, furosemide, and acetylsalicylic acid. These results are in line with those described by other authors [30,43]. When the ATC classification third level was considered, drug consumption is concentrated in several groups in the polymedicated population. The most consumed pharmacological subgroup was A02B (drugs for peptic ulcer) to prevent those adverse reactions caused by other medicines administered to NH residents. Antithrombotic agents (B01A) and diuretics (C03C) are also among those most consumed drugs, which is in agreement with other authors [24,25,43]. It is also interesting the high use of anxiolytics in the polypharmacy group (43.4%). As reported in other studies, their use is more common among institutionalized people [14,44]. However, this high consumption is a matter of concern, as they should not be prescribed on a long-term basis. Thus, efforts should be made to improve medication usage in NH residents.

Several attempts to reduce polypharmacy in clinical settings have been made [45–47]. Some countries like Belgium have published guidance on how to prescribe for older people [25]. In Spain, potentially inappropriate prescribing in older people have been reviewed in accordance with the STOPP/START criteria [48]. This would be one of the strategies that could help to optimize drug therapy. These studies should be carried out periodically, as they allow to assess the actual use of medicines and the associated factors, complementing information obtained from drug utilization studies. On the other hand, non-pharmacological approaches should also be considered. The HALT study has shown a successful and sustainable reduction in regular antipsychotic use based on an individualized deprescribing intervention and education/training of healthcare professionals (GPs, pharmacists, and nurses) [49]. Regarding people with dementia, non-pharmacological approaches have been recommended by international guidelines as first-line treatments, considering pharmacological approaches only when the former fail [50,51]. Among these non-pharmacological approaches, music therapy or psychological treatments have been described [52].

Some limitations need to be recognized in the present study. It was carried out in only one NH, and the sample could not be nationally representative, although the number of institutionalized persons was high. On the other hand, it did not include complementary or OTC drugs, which would imply that the level of polypharmacy could be even higher.

Our study also shows several strengths. Up to our knowledge, it is the first study carried out in a Spanish NH from a geographical area with a high prevalence of aged people in which polypharmacy is extensively studied. We have found only one study in which these factors associated with polypharmacy were analyzed but in non-institutionalized older people from Castile-Leon (Spain) [53]. On the other hand, data were directly retrieved from primary sources (neither questionnaires nor retrospective databases) such as medication charts and information obtained from the physician, being consequently more exhaustive.

Our results provide a high estimate for the prevalence rates of polypharmacy and excessive polypharmacy in NH. Up to 26.6 and 52.0% of residents aged 75–84 and 85–94
showed polypharmacy (29.6 and 56.3% on excessive polypharmacy, respectively), which is worrying. The study confirms that polypharmacy and excessive polypharmacy are unfortunately common among NH residents in Europe [54].

Health professionals can have an important role in reducing polypharmacy in NH by implementing alternatives like deprescribing guidelines or multidisciplinary education in geriatric pharmacotherapy. As an interprofessional team, each member plays a role in helping to reduce medication use and monitor the adverse effects.

The use of multiple medicines may be clinically appropriate for some institutionalized elderly, but it is important to identify those who may be at risk of adverse health outcomes as a result of inappropriate polypharmacy. This is critical to facilitate the deprescribing of inappropriate medications and the optimal use of appropriate medications, but clinical practice guidelines should be periodically updated.

5. Conclusions

Our study has shown that polypharmacy is a major problem in the NH assessed. Almost a quarter of the participants aged 75–84, and more than a half of those aged 85–94 are exposed to polypharmacy and excessive polypharmacy, which is of concern. A mean of 7.02 ± 3.31 drugs was consumed by residents. Interventions should be focused on NH residents hospitalized in the last year and those in contact with the GP in the past two months. Attempts to reduce the use of inappropriate drugs should be made. Health professionals play an important role as a checkpoint to evaluate the necessity of drug treatment, especially among the elderly.

Supplementary Materials: The following are available online at https://www.mdpi.com/1660-4601/18/4/2037/s1. Table S1: Characteristics of the most frequently diagnosed clinical problems in the NH residents stratified by the level of polypharmacy. Table S2: Characteristics of the anatomical group (1st level ATC) among NH residents stratified by the level of polypharmacy. Table S3: A Characteristics of the 10 most commonly used drug groups (3rd level ATC) among NH residents stratified by the level of polypharmacy. Table S4: Factors associated with the consumption of the three most used anatomical groups in the NH studied (reference category: non-consumption).

Author Contributions: Conceptualization, J.J.G., N.F. and R.D.; methodology, C.L., R.C. and R.D.; formal analysis, A.M.S., J.S., M.J.D. and M.S.; investigation, R.D. and J.S.; resources, C.L., R.C. and R.D.; data curation, R.D.; writing—original draft preparation, A.M.S.; M.S.; N.F.; R.D.; visualization, C.L.; supervision, C.L. and R.D.; project administration, C.L. and R.D. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study was approved by the Institutional Review Board of the Nursing Home and the Ethics Committee of the University of Leon (ULE-0382018).

Informed Consent Statement: Not applicable.

Data Availability Statement: Data are available on request from the corresponding author.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Organisation for Economic Co-operation and Development. Demographic trends. Available online: https://www.oecd-ilibrary.org/sites/4dd50c09-en/1/3/11/1/index.html?itemId=/content/publication/4dd50c09-en&_csp_=82587932df7c06a6a3f9dab95304095d&itemIGO=oecd&itemContentType=book (accessed on 22 December 2020).
2. Fernandez, J.N. Informe 2016. Las Personas Mayores en España. Datos Estadísticos Estatales y por Comunidades Autónomas; Imserso: Madrid, Spain, 2017.
3. Instituto Nacional de Estadística Indice de Envejecimiento. Available online: https://www.ine.es/jaxiT3/Tabla.htm?t=1489 (accessed on 22 December 2020).
4. WHO Centre for Health Development. A Glossary of Terms for Community Health Care and Services for Older Persons; WHO Centre for Health Development: Kobe, Japan, 2014.
5. Viktil, K.K.; Blix, H.S.; Moger, T.A.; Reikvam, A. Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems. Br. J. Clin. Pharmacol. 2007, 63, 187–195. [CrossRef] [PubMed]
6. Ahmed, B.; Nanji, K.; Mujeeb, R.; Patel, M.J. Effects of polypharmacy on adverse drug reactions among geriatric outpatients at a tertiary care hospital in Karachi: A prospective cohort study. PLoS ONE 2014, 9, e112133. [CrossRef] [PubMed]

7. Gnjidic, D.; Hilmer, S.N.; Blyth, F.M.; Naganathan, V.; Waite, L.; Seibel, M.J.; McChliren, A.J.; Cumming, R.G.; Handselman, D.J.; Le Couteur, D.G. Polypharmacy cutoff and outcomes: Five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J. Clin. Epidemiol. 2012, 65, 989–995. [CrossRef]

8. Diez-Manglano, J.; Giménez-López, M.; García-Horna, V.; Sevil-Puras, M.; Castellar-Otin, E.; González-García, P.; Fiteni-Mera, I.; Morlanes-Navarro, T. Excessive polypharmacy and survival in polypathological patients. Eur. J. Clin. Pharmacol. 2015, 71, 733–739. [CrossRef]

9. Haider, S.I.; Johnell, K.; Thorslund, M.; Fastbom, J. Analysis of the association between polypharmacy and socioeconomic position among elderly aged ≥ 77 years in Sweden. Clin. Ther. 2008, 30, 419–427. [CrossRef] [PubMed]

10. Slabaugh, S.; Maio, V.; Abouzaid, S.; Templin, M. Prevalence and predictors of polypharmacy amongst elderly patients: A population-based cohort study. Value Health 2010, 13, A181. [CrossRef]

11. Koper, D.; Kamenski, G.; Flamm, M.; Böhmdorfer, B.; Sönntichsen, A. Frequency of medication errors in primary care patients with polypharmacy. Fam. Pract. 2013, 30, 313–319. [CrossRef] [PubMed]

12. Fulton, M.; Allen, E. Polypharmacy in the elderly: A literature review. J. Am. Acad. Nurse Pract. 2005, 17, 123–132. [CrossRef]

13. Kantor, E.; Rehm, C.; Haas, J.; Chan, A.; Giovannucci, E. Trends in prescription drug use among adults in the United States from 1999–2012. JAMA Intern. Med. 2015, 314, 1818–1830. [CrossRef] [PubMed]

14. Scott, I.A.; Hilmer, S.N.; Reeve, E.; Potter, K.; Le Couteur, D.; Rigby, D.; Gnjidic, D.; Del Mar, C.B.; Roughead, E.E.; Page, A.; et al. Reducing inappropriate polypharmacy: The process of deprescribing. JAMA Intern. Med. 2015, 175, 827–834. [CrossRef] [PubMed]

15. Davies, E.; O’Mahony, M. Adverse drug reactions in special populations—The elderly. Br. J. Clin. Pharmacol. 2015, 80, 796–807. [CrossRef] [PubMed]

16. Morley, J.E.; Caplan, G.; Cesari, M.; Dong, B.; Flaherty, J.H.; Grossberg, G.T.; Holmerova, I.; Katz, P.R.; Koopmans, R.; Little, M.O.; et al. International survey of nursing home research priorities. J. Am. Med. Dir. Assoc. 2014, 15, 309–312. [CrossRef] [PubMed]

17. Rolland, Y.; de Souto Barreto, P. Research can improve care in the nursing home. J. Am. Med. Dir. Assoc. 2013, 14, 233–235. [CrossRef] [PubMed]

18. Cuschieri, S. The STROBE guidelines. Saudi J. Anaesth. 2019, 13, 31–34. [CrossRef] [PubMed]

19. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC Classification and DDD Assignment 2019, 22nd ed.; WHO Collaborating Centre for Drug Statistics Methodology: Oslo, Norway, 2018.

20. Kaufman, D.W.; Kelly, J.P.; Rosenberg, L.; Anderson, T.E.; Mitchell, A.A. Recent patterns of medication use in the ambulatory adult population of the United States: The Slone survey. J. Am. Med. Assoc. 2002, 287, 337–344. [CrossRef]

21. Jyrkkä, J.; Enlund, H.; Korhonen, M.J.; Sulkava, R.; Hartikainen, S. Polypharmacy status as an indicator of mortality in an elderly population. Drugs Aging 2009, 26, 1039–1048. [CrossRef] [PubMed]

22. Haider, S.I.; Johnell, K.; Weitof, G.R.; Thorslund, M.; Fastbom, J. The influence of educational level on polypharmacy and inappropriate drug use: A register-based study of more than 600,000 older people. J. Am. Geriatr. Soc. 2009, 57, 62–69. [CrossRef]

23. Hövstadius, B.; Hövstadius, K.; Åstrand, B.; Petersson, G. Increasing polypharmacy—An individual-based study of the Swedish population 2005–2008. BMC Clin. Pharmacol. 2010, 10, 16. [CrossRef] [PubMed]

24. Onder, G.; Liberoti, R.; Fiallova, D.; Topinkova, E.; Tosato, M.; Danese, P.; Gallo, P.F.; Carpenter, I.; Finne-Soveri, H.; Gindin, J.; et al. Polypharmacy in nursing home in Europe: Results from the SHELTER study. J. Gerontol. Ser. A Biol. Sci. Med. Sci. 2012, 67A, 698–704. [CrossRef] [PubMed]

25. Wallkiers, D.; Van der Heyden, J.; Taffreau, J. Factors associated with excessive polypharmacy in older people. Arch. Public Health 2015, 73, 1–12. [CrossRef]

26. O’Dwyer, M.; Peklar, J.; McCallion, P.; McCarron, M.; Henman, M.C. Factors associated with polypharmacy and excessive polypharmacy in older people with intellectual disability differ from the general population: A cross-sectional observational nationwide study. BMJ Open 2016, 6. [CrossRef]

27. Elseviers, M.M.; Vander Stichele, R.R.; Van Bortel, L. Drug utilization in Belgian nursing homes: Impact of residents’ and institutional characteristics. Pharmacopédiologie. Drug Saf. 2010, 19, 1041–1048. [CrossRef]

28. Beloosesky, Y.; Nenaydenko, O.; Gross Nevo, R.F.; Adunsky, A.; Weiss, A. Rates, variability, and associated factors of polypharmacy in nursing home patients. Clin. Interv. Aging 2013, 8, 1585–1590. [CrossRef]

29. Castioni, J.; Marques-Vidal, P.; Abolhassani, N.; Vollenweider, P.; Waebier, G. Prevalence and determinants of polypharmacy in Switzerland: Data from the CoLaus study. BMC Health Serv. Res. 2017, 17, 840. [CrossRef]

30. Moore, K.L.; Patel, K.; John Boscardin, W.; Steinman, M.A.; Ritchie, C.; Schwartz, J.B. Medication burden attributable to chronic comorbid conditions in the very old and vulnerable. PLoS ONE 2018, 13, e0196109. [CrossRef]

31. Blanco-Reina, E.; Ariza-Zafra, G.; Ocaña-Riola, R.; León-Ortiz, M.; Bellido-Estévez, I. Optimizing elderly pharmacotherapy: Polypharmacy vs. undertreatment. Are these two concepts related? Eur. J. Clin. Pharmacol. 2015, 71, 199–207. [CrossRef]

32. Fried, T.R.; O’Leary, J.; Towle, V.; Goldstein, M.K.; Trentalange, M.; Martin, D.K. Health outcomes associated with polypharmacy in community-dwelling older adults: A systematic review. J. Am. Geriatr. Soc. 2014, 62, 2261–2272. [CrossRef]

33. Lopes, L.M.; de Figueiredo, T.P.; Costa, S.C.; Reis, A.M.M. Use of potentially inappropriate medications by the elderly at home. Ciencia Saude Coletiva 2016, 21, 3429–3438. [CrossRef]
34. Wang, R.; Chen, L.; Fan, L.; Gao, D.; Liang, Z.; He, J.; Gong, W.; Gao, L. Incidence and effects of polypharmacy on clinical outcome among patients aged 80+: A five-year follow-up study. *PLoS ONE* 2015, 10, e0142123. [CrossRef] [PubMed]

35. Maher, R.L.; Hanlon, J.T.; Hajjar, E.R. Clinical consequences of polypharmacy in elderly. *Expert Opin. Drug Saf.* 2014, 13, 57–65. [CrossRef] [PubMed]

36. Charlesworth, C.J.; Smit, E.; Lee, D.S.H.; Alramadhan, F.; Odden, M.C. Polypharmacy among adults aged 65 years and older in the United States: 1988–2010. *J. Gerontol. Ser. A Biol. Sci. Med. Sci.* 2015, 70, 989–995. [CrossRef]

37. Lutz, B.H.; Miranda, V.I.A.; Bertoldi, A.D. Potentially inappropriate medications among older adults in Pelotas, Southern Brazil. *Revista de Saúde Pública* 2017, 51, 1–12. [CrossRef]

38. Gómez, C.; Vega-Quiroga, S.; Bermejo-Pareja, F.; Medrano, M.J.; Louis, E.D.; Benito-León, J. Polypharmacy in the elderly: A marker of increased risk of mortality in a population-based prospective study (NEDICES). *Gerontology* 2015, 61, 301–309. [CrossRef]

39. Lindley, R.I. Drug trials for older people. *J. Gerontol. Ser. A Biol. Sci. Med. Sci.* 2012, 67A, 152–157. [CrossRef]

40. Holmes, H.M. Rational prescribing for patients with a reduced life expectancy. *Clin. Pharmacol. Ther.* 2009, 85, 103–107. [CrossRef]

41. American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated beers criteria for potentially inappropriate medication use in older adults. *J. Am. Geriatr. Soc.* 2015, 63, 2227–2246. [CrossRef]

42. O’Mahony, D.; O’Sullivan, D.; Stephen, B.; O’Connor, M.; Ryan, C.; Gallagher, P. STOPP/START criteria for potentially inappropriate prescribing in older people: Version 2. *Age Ageing* 2015, 44, 213–218. [CrossRef]

43. Wastesson, J.W.; Miguez, A.C.; Fastbom, J.; Maioli, S.; Johnell, K. The composition of polypharmacy: A register-based study of Swedes aged 75 years and older. *PLoS ONE* 2018, 13, e0194892. [CrossRef] [PubMed]

44. Moore, K.L.; Boscardin, W.J.; Steinman, M.A.; Schwartz, J.B. Age and sex variation in prevalence of chronic medical conditions in older residents of U.S. nursing homes. *J. Am. Geriatr. Soc.* 2012, 60, 756–764. [CrossRef] [PubMed]

45. Liu, L.M. Deprescribing: An approach to reducing polypharmacy in nursing home residents. *J. Nurse Pract.* 2014, 10, 136–139. [CrossRef]

46. Johansson, T.; Abuzahra, M.E.; Keller, S.; Mann, E.; Faller, B.; Sommerauer, C.; Höck, J.; Löf, C.; Köchling, A.; Schuler, J.; et al. Impact of strategies to reduce polypharmacy on clinically relevant endpoints: A systematic review and meta-analysis. *Br. J. Clin. Pharmacol.* 2016, 82, 532–548. [CrossRef]

47. Tommelein, E. Deprescribing in nursing homes is safe and should be pursued. *Evid. Based Nurs.* 2018, 21, 53. [CrossRef]

48. Cruz-Esteve, I.; Marsal-Mora, J.R.; Galindo-Ortego, G.; Galván-Santiago, L.; Serrano-Godoy, M.; Ribes-Murillo, E. Análisis poblacional de la prescripción potencialmente inadecuada en ancianos según criterios STOPP/START (estudio STARTREC). *Atención Primaria* 2017, 49, 166–176. [CrossRef] [PubMed]

49. Brodaty, H.; Aerts, L.; Harrison, F.; Jessop, T.; Cations, M.; Chenoweth, L.; Shell, A.; Popovic, G.C.; Heffernan, M.; Hilmer, S.; et al. Antipsychotic deprescription for older adults in long-term care: The HALT study. *J. Am. Med. Dir. Assoc.* 2018, 19, 592–600. [CrossRef]

50. Reus, V.I.; Fochtmann, L.J.; Eyler, A.E.; Hilty, D.M.; Horvitz-Lennon, M.; Jibson, M.D.; Lopez, O.L.; Mahoney, J.; Pasic, J.; Tan, Z.S.; et al. The American Psychiatric Association Practice Guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. *Am. J. Psychiatry* 2016, 173, 543–546. [CrossRef] [PubMed]

51. Bjerre, L.M.; Farrell, B.; Hogel, M.; Graham, L.; Lemay, G.; McCarthy, L.; Raman-Wilms, L.; Rojas-Fernandez, C.; Sinha, S.; Thompson, W.; et al. Deprescribing antipsychotics for behavioural and psychological symptoms of dementia and insomnia: Evidence-based clinical practice guideline. *Can. Fam. Physician* 2018, 64, 17–27.

52. Harrison, S.L.; Cations, M.; Jessop, T.; Hilmer, S.N.; Sawan, M.; Brodaty, H. Approaches to deprescribing psychotropic medications for changed behaviours in long-term care residents living with dementia. *Drugs Aging* 2019, 36, 125–136. [CrossRef]

53. Frutos, E.; Carlos, J.; Corral, M.; Galindo, P. Factores asociados a la polifarmacia en población anciana no institucionalizada. Análisis de la submuestra de la Encuesta Nacional de Salud 2006 para personas mayores de Castilla y León. *Rev. Española Geriatría Gerontol.* 2011, 46, 303–306. [CrossRef]

54. Schneider, R.; Reinau, D.; Schur, N.; Blozik, E.; Frh, M.; Signorell, A.; Meier, C.R.; Schwenkglenks, M. Drug prescription patterns, polypharmacy and potentially inappropriate medication in Swiss nursing homes: A descriptive analysis based on claims data. *Swiss Med. Wkly.* 2019. [CrossRef] [PubMed]